Axon Enterprise (NASDAQ:AXON) Price Target Raised to $725.00

Axon Enterprise (NASDAQ:AXON) had its target price upped by JMP Securities from $610.00 to $725.00 in a report published on Tuesday,Benzinga reports. They currently have a market outperform rating on the biotechnology company’s stock.

Several other analysts have also weighed in on AXON. Needham & Company LLC boosted their target price on shares of Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Robert W. Baird increased their price objective on shares of Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a research note on Friday, December 6th. TD Cowen assumed coverage on Axon Enterprise in a research note on Wednesday, January 8th. They issued a “buy” rating and a $700.00 target price for the company. The Goldman Sachs Group increased their price target on Axon Enterprise from $500.00 to $700.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. Finally, Northland Securities boosted their price objective on Axon Enterprise from $365.00 to $550.00 and gave the company an “outperform” rating in a research report on Monday, November 11th. One investment analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Axon Enterprise presently has an average rating of “Moderate Buy” and an average target price of $542.15.

Axon Enterprise Stock Performance

Axon Enterprise stock opened at $677.40 on Tuesday. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32. The stock has a 50 day moving average of $622.79 and a 200-day moving average of $491.30. The stock has a market cap of $51.66 billion, a P/E ratio of 175.04, a price-to-earnings-growth ratio of 6.54 and a beta of 1.05. Axon Enterprise has a 52 week low of $255.68 and a 52 week high of $698.67.

Insiders Place Their Bets

In other Axon Enterprise news, insider Jeffrey C. Kunins sold 1,035 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $624.47, for a total value of $646,326.45. Following the completion of the transaction, the insider now directly owns 124,243 shares in the company, valued at approximately $77,586,026.21. This represents a 0.83 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $604.07, for a total value of $271,831.50. Following the transaction, the director now directly owns 6,929 shares of the company’s stock, valued at approximately $4,185,601.03. This represents a 6.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,545 shares of company stock worth $30,721,337 over the last ninety days. Corporate insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Axon Enterprise

A number of hedge funds have recently added to or reduced their stakes in AXON. Groupama Asset Managment acquired a new stake in Axon Enterprise in the 3rd quarter valued at $200,000. Massachusetts Financial Services Co. MA acquired a new position in shares of Axon Enterprise during the third quarter valued at about $120,553,000. International Assets Investment Management LLC bought a new stake in shares of Axon Enterprise during the third quarter worth about $871,860,000. Proficio Capital Partners LLC acquired a new stake in shares of Axon Enterprise in the 4th quarter worth about $78,414,000. Finally, Westfield Capital Management Co. LP raised its holdings in shares of Axon Enterprise by 12.2% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,175,328 shares of the biotechnology company’s stock worth $469,661,000 after acquiring an additional 127,769 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.